MYH11 and myelodysplastic syndrome: Unlike their true MDS counterparts, these cases typically lack the tell-tale dysplasia seen in MDS and they will have mutations that are otherwise exclusively seen in AML such as RUNX1::RUNX1T1, CBF::MYH11, or mutated NPM1. These patients have demographic and disease characteristics similar to patients with de novo AML, and the disease behavior is also more akin to that of de novo AML.